Migraine infusion, typically involving dihydroergotamine (DHE), is a vasoactive medication that acts as a potent serotonin receptor agonist and ergot alkaloid with selective vasoconstrictor properties in the cranial vasculature. It works by reducing neurogenic inflammation, constricting cranial blood vessels, and interrupting pain signaling pathways, thereby providing rapid and effective relief for acute cluster headache episodes. The medication demonstrates significant efficacy in aborting cluster headache attacks by modulating neurovascular mechanisms and reducing inflammatory responses.